Cyclophosphamide trials for Lung cancer

All Cyclophosphamide trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Cyclophosphamide for Lung cancer

• A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
  NCT07613723 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
  NCT03412877 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 2 locations
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
  NCT06885697 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
  NCT05296564 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
  NCT05681780 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
  NCT07510815 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
  NCT04959175 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 85 Years · Sex: All (male and female) · 2 locations
• START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
  NCT05492682 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
  NCT04282044 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
  NCT02133196 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
  NCT06538012 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Cyclophosphamide for Lung cancer?

13 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.